Literature DB >> 18159461

T cell costimulatory molecules in anti-viral immunity: Potential role in immunotherapeutic vaccines.

Tania H Watts, Edward M Bertram, Jacob Bukczynski, Tao Wen.   

Abstract

T lymphocyte activation is required to eliminate or control intracellular viruses. The activation of T cells requires both an antigen specific signal, involving the recognition of a peptide/major histocompatibility protein complex by the T cell receptor, as well as additional costimulatory signals. In chronic viral diseases, T cell responses, although present, are unable to eliminate the infection. By providing antigens and costimulatory molecules together, investigators may be able to increase and broaden the immune response, resulting in better immunological control or even elimination of the infection. Recent progress in understanding the function of costimulatory molecules suggests that different costimulatory molecules are involved in initial immune responses than are involved in recall responses. These new developments have important implications for therapeutic vaccine design. In this review the authors discuss the function of T cell costimulatory molecules in immune system activation and their potential for enhancing the efficacy of therapeutic vaccines.

Entities:  

Keywords:  Immunity; Lymphocytes; Therapeutic vaccines; Vaccination; Viral infection

Year:  2003        PMID: 18159461      PMCID: PMC2094939          DOI: 10.1155/2003/214034

Source DB:  PubMed          Journal:  Can J Infect Dis        ISSN: 1180-2332


  72 in total

Review 1.  Innate immune recognition.

Authors:  Charles A Janeway; Ruslan Medzhitov
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

Review 2.  Genetically modified viruses: vaccines by design.

Authors:  J R Stephenson
Journal:  Curr Pharm Biotechnol       Date:  2001-03       Impact factor: 2.837

3.  ICOS co-stimulatory receptor is essential for T-cell activation and function.

Authors:  C Dong; A E Juedes; U A Temann; S Shresta; J P Allison; N H Ruddle; R A Flavell
Journal:  Nature       Date:  2001-01-04       Impact factor: 49.962

4.  Absence of B7-dependent responses in CD28-deficient mice.

Authors:  J M Green; P J Noel; A I Sperling; T L Walunas; G S Gray; J A Bluestone; C B Thompson
Journal:  Immunity       Date:  1994-09       Impact factor: 31.745

5.  Decline in CD28+ T cells in centenarians and in long-term T cell cultures: a possible cause for both in vivo and in vitro immunosenescence.

Authors:  R B Effros; N Boucher; V Porter; X Zhu; C Spaulding; R L Walford; M Kronenberg; D Cohen; F Schächter
Journal:  Exp Gerontol       Date:  1994 Nov-Dec       Impact factor: 4.032

6.  Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection.

Authors:  Bruce L Levine; Wendy B Bernstein; Naomi E Aronson; Katia Schlienger; Julio Cotte; Steven Perfetto; Mary J Humphries; Silvia Ratto-Kim; Deborah L Birx; Carolyn Steffens; Alan Landay; Richard G Carroll; Carl H June
Journal:  Nat Med       Date:  2002-01       Impact factor: 53.440

7.  Costimulation of human CD28- T cells by 4-1BB ligand.

Authors:  Jacob Bukczynski; Tao Wen; Tania H Watts
Journal:  Eur J Immunol       Date:  2003-02       Impact factor: 5.532

Review 8.  CTLA-4: new insights into its biological function and use in tumor immunotherapy.

Authors:  Jackson G Egen; Michael S Kuhns; James P Allison
Journal:  Nat Immunol       Date:  2002-07       Impact factor: 25.606

Review 9.  Adenoviruses as vectors for delivering vaccines to mucosal surfaces.

Authors:  L A Babiuk; S K Tikoo
Journal:  J Biotechnol       Date:  2000-09-29       Impact factor: 3.307

10.  Evolution of a complex T cell receptor repertoire during primary and recall bacterial infection.

Authors:  D H Busch; I Pilip; E G Pamer
Journal:  J Exp Med       Date:  1998-07-06       Impact factor: 14.307

View more
  2 in total

1.  Combination Therapy of Novel Oncolytic Adenovirus with Anti-PD1 Resulted in Enhanced Anti-Cancer Effect in Syngeneic Immunocompetent Melanoma Mouse Model.

Authors:  Mariangela Garofalo; Laura Bertinato; Monika Staniszewska; Magdalena Wieczorek; Stefano Salmaso; Silke Schrom; Beate Rinner; Katarzyna Wanda Pancer; Lukasz Kuryk
Journal:  Pharmaceutics       Date:  2021-04-14       Impact factor: 6.321

2.  T Cells Modified with CD70 as an Alternative Cellular Vaccine for Antitumor Immunity.

Authors:  Sang-Eun Lee; A-Ri Shin; Hyun-Jung Sohn; Hyun-Il Cho; Tai-Gyu Kim
Journal:  Cancer Res Treat       Date:  2020-02-14       Impact factor: 4.679

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.